NCT01585233 - A Multiple Dose Escalation Study of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

June 30, 2014

Study Completion Date

January 7, 2015

Conditions

Psoriasis

Interventions

DRUG

ASKP1240

Intravenous

DRUG

Placebo

Intravenous

Trial Locations (13)

1010

Auckland Clinical Studies, Auckland

3110

P3 Research, Tauranga, Tauranga

3121

Epworth Hospital, Richmond

4102

Specialist Connect, Brisbane

5000

CMAX, Adelaide

6009

Linear Research, Nedlands

6021

P3 Research, Wellington, Wellington

8011

Christchurch Clincial Studies Trust, Ltd., Christchurch

E1C 8X3

Durondel C.P. Inc, The Dermatology Clinic, Moncton

A1C 2H5

New Lab Clinical Research, St. John's

L4M 6L2

Ultranova Skincare, Barrie

N2J 1C4

K. Papp Clinical Research, Waterloo

H2K 4L5

Innovaderm Research, Inc., Montreal

All Listed Sponsors

collaborator

Kyowa Kirin Co., Ltd.

INDUSTRY

lead

Astellas Pharma Global Development, Inc.

INDUSTRY